News | Cath Lab | October 27, 2016

Better Prognosis for Some PCI Patients When Operators Perform More Procedures

Patients needing more complex PCIs have better outcomes, according to Chinese study

PCI, operator volume, China study, JACC, outcomes

October 27, 2016 — Volume matters when it comes to who does certain procedures to removing heart-attack causing blockages from arteries, according to a new study published recently in JACC: Cardiovascular Interventions.

Researchers in China found patients undergoing left main coronary artery percutaneous coronary intervention (PCI) had better outcomes when the procedure was performed by experienced, high-volume operators — even though the patients treated by the experienced operators tended to have more complex and extensive heart disease. Left-main PCI can be used to treat patients with advanced coronary artery disease. In this procedure, a drug-eluting stent is placed in the left main coronary artery to open the blockage. The technique is minimally invasive and has been associated with fewer complications, short hospital stays and quicker recovery time than coronary artery bypass graft (CABG) surgery.

The researchers examined the records of 1,948 patients who underwent left-main PCI between January 2004 and December 2011, with 25 operators performing the procedure. Of those patients, 1,422 (73 percent) were treated by seven experienced, high-volume operators and 526 (27 percent) patients were treated by 18 less experienced, low-volume operators. High-volume operators performed a mean of 25 left-main PCIs per year, while low-volume operators performed a mean of four left-main PCIs per year. 

Patients treated by high-volume operators had better short- and long-term outcomes. Death within 30 days was 0.6 percent with high-volume operators and 2.1 percent with low-volume operators. There was no significant difference in rates of heart attack, and stroke over the same time period were lower in patients treated by high-volume operators. Patients of high-volume operators also had lower risks of cardiac death and all-cause mortality, as well as a trend toward a decreased risk of stent thrombosis.

After three years, patients treated by experienced, high-volume operators experienced a significantly lower risk of cardiac death.

These trends were observed even though patients who underwent left-main PCI with a high-volume operator had more extensive coronary artery disease and underwent more technically complex procedures. High-volume operators were also more likely to use first-generation, rather than superior second-generation, drug-eluting stents.

This is the first study to conclusively demonstrate that operator experience impacts the prognosis of patients who undergo high-risk PCI.

“Our findings suggest that high-risk and complex procedures, such as left-main PCI, should be reserved to a limited number of experienced operators in order to achieve the best outcomes,” said Yuejin Yang, M.D., from the department of cardiology at Fu Wai Hospital in Beijing and an author of the study. “Alternatively, less experienced operators could perform left-main PCI under the close supervision and mentorship of an experienced operator until they acquire sufficient skill and technique to become independent.”

In an editorial comment accompanying the study, Ralph G. Brindis, M.D., MPH, MACC, and Gregory J. Dehmer, M.D., MACC, examined data from the American College of Cardiology’s (ACC) National Cardiovascular Data Registry’s (NCDR) CathPCI Registry to determine the  amount of left-main PCI’s performed by high- and low-volume operators in the United States. They found that for left-main PCIs performed between April 2015 and March 2016, only 1 percent of operators would be considered high-volume based on the study’s criteria of having performed at least 15 left-main PCI’s per year for at least three consecutive years. Additionally, these operators performed only 8.4 percent of these annual procedures in the United States.

“These numbers are a stark contrast compared with the results of the study by Yang and colleagues and perhaps should be a wake-up call to the interventional community,” Brindis and Dehmer said. “The concept of a ‘Center of Excellence’ has been widely promoted and, frankly, overused to the point it now has little meaning. The study findings show that a ‘Center of Excellence’ for left-main PCI should be one with experienced, high-volume operators that can demonstrate good outcomes.”

Related NCDR CathPCI Registry articles:

• Radial Access, Same-Day Cardiac Procedure Could Save $300 Million Annually

• New Report Highlights National Trends in Heart Disease Treatments

• Study Finds Significant Variability in Doctors' Angioplasty Death Rates

 

For more information: www.jacc.org

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major